Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04631289
Other study ID # met on AKI
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 1, 2020
Est. completion date November 10, 2020

Study information

Verified date November 2020
Source Second Affiliated Hospital of Guangzhou Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

More than 50% of ICU patients suffer from Acute kidney injury (AKI). Metformin shows protective properties in kidney disease. Our study aimed to validate AKI incidence among diabetes patients in the ICU with or without preadmission metformin exposure. We included non-AKI patients with type 2 diabetes in Medical Information Mart for Intensive Care (MIMIC)-III database. Incidence of AKI and mortality were compared between those with and without preadmission prescriptions.


Description:

Emerged as a major public healthy problem, Acute kidney injury (AKI) is now influencing millions of people worldwide and leading to reduced survival, increased progression of latent chronic kidney disease (CKD), and even new onset of CKD. More than half of intensive care unit (ICU) patients underwent AKI in a recent multinational cross-sectional study, often resulting in the need for renal replacement therapy with a high socio-economic impact for the patients.The effective precaution and treatment strategy remains limited. As the most general and first-line biguanide antihyperglycemic drug, metformin has anti-inflammatory characteristics and is related with decreased all-cause mortality compared with other antihyperglycemics.. In some clinical trials and experimental studies conducted on divergent rodent models representing various types of kidney diseases going from AKI to CKD, metformin has been shown beneficial effects on the kidney. Moreover, preadmission metformin exposure is associated with a lower rate of 28-day mortality among AKI patients showed in several clinical studies. However, in critical care patients with type 2 diabetes, the evidence of preadmission metformin usage decreasing a risk of AKI incidence is still absented. Therefore we performed a retrospective cohort study to validate the association of preadmission metformin exposure and AKI incidence in patients with diabetes in the ICU .


Recruitment information / eligibility

Status Completed
Enrollment 3841
Est. completion date November 10, 2020
Est. primary completion date September 1, 2020
Accepts healthy volunteers No
Gender All
Age group 16 Years to 90 Years
Eligibility Inclusion Criteria: - type 2 diabetes - >16 years old and <90 years old - without AKI Exclusion Criteria: - CKD - data error - type 1 diabetes - diabetes patients with pregnancy - no metformin record - with AKI

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China SAHGuangzhouMU Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital of Guangzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of AKI AKI was defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. within 7days in the ICU
See also
  Status Clinical Trial Phase
Completed NCT04112953 - Intraoperative Transesophageal Echocardiography Assessment of Portal Vein Flow and Renal Resistive Index As a Predictor of Acute Kidney Injury After Cardiac Surgery: A Prospective Observational Study
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Active, not recruiting NCT04008810 - Serum Neutrophil Gelatinase-associated Lipocalins (NGAL) and Chronic Kidney Disease
Recruiting NCT04597034 - Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19 N/A
Completed NCT04458571 - Effect of CRRT Duration on Solute Removal
Recruiting NCT04114747 - Renal Physiology During Continuous Renal Replacement Therapy N/A
Completed NCT05094154 - Effect of Antibiotic Choice On ReNal Outcomes (ACORN) Phase 4
Enrolling by invitation NCT04491227 - Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
Not yet recruiting NCT05382078 - Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients
Recruiting NCT04351906 - Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome N/A
Recruiting NCT06416761 - Genetics in the Progression of Nephropathies
Completed NCT04762524 - The Impact of CRRT Modality on Filter Life N/A
Completed NCT04048525 - Cytokine Removal With CVVHD Compared to CVVH N/A
Completed NCT04788394 - Renal Involvement in Hospitalized Children With COVID-19
Recruiting NCT04474249 - Follow-up of Critical COVID-19 Patients
Completed NCT04407156 - Epidemiology of Acute Kidney Injury in COVID19 Disease in United Kingdom
Completed NCT04517630 - Renal Biomarkers in AKI and COVID-19
Recruiting NCT04895384 - El DORADO STUDY (Evaluation of Delivery of Oxygen on Renal, Arrhythmia and Delirium Outcomes Study)
Completed NCT03070353 - Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury Phase 2/Phase 3